LEGN
Legend Biotech Corporation
Biotechnology · Healthcare · United States
22.30
close · 2026-10-29
value
64
cheaper than peers64
quality
69
stronger fundamentals69
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 3.69× | 82 |
| forward P/E | 21.24× | 51 |
| price to book | 3.51× | 49 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | -16.3% | 71 |
| return on equity | -25.2% | 71 |
| revenue growth | 56.5% | 68 |
| debt to equity | 40.2% | 33 |
4 of 4 measures available
Facts
| market cap | $4B |
| free cash flow | -$55.8M |
| employees | 3,100 |
| first trade | 2020-06-05 |
| next earnings | 2026-11-10 |
| fundamentals updated | 2026-08-11 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.62 | -0.96 | -2.94 | -2.80 |
| free cash flow | -$128.8M | -$158.1M | -$416.0M | -$223.6M |
| net income | -$296.8M | -$177.0M | -$518.3M | -$446.3M |
| revenue | $1.03B | $627.3M | $285.1M | $117.0M |
| unusual items | -$168.8M | $109.3M | -$28.2M | $21.5M |